Table 1.
GVHD-associated angiomatosis summary
| Age | Sex | Disease | Graft source/Sex/Relation/HLA match |
TBI | Time to sclerotic GVHD (months) |
Number of systemic therapies |
Time to documented angiomatosis (months) |
Location | LE edema |
Treatment | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 62 | F | AML | BM/-/-/Full | U | 36 | 7 | 249 | L LE | N | N/A |
| 2 | 58 | F | AML | PB/M/Sibling/Full | Y | 16 | 4 | 28 | B/L LE | Y | Propranolol sirolimus |
| 3 | 67 | F | AML | PB/F/Unrelated/Full | N | 13 | 2 | 37 | Right LE |
Y | Shave cauterization |
| 4 | 57 | F | MDS | BM/M/Unrelated/5/6 | Y | 18 | 6 | 29 | Right flank, chest |
N | Shave |
| 5 | 53 | M | Metastatic RCC |
PB/F/Sibling/Full | N | 24 | 4 | 34 | Chest, flank |
N | N/A |
| 6 | 39 | F | AML | PB/F/Sibling/Full | Y | 12 | 4 | 21 | L LE | Y | N/A |
| 7 | 49 | M | pre-B ALL |
PB/F/Sibling/Full | Y | 36 | 4 | 82 | B/L LE, R shoulder |
Y | N/A |
| 8 | 57 | F | MM | -/F/Sibling/Full | Y | 24 | 5 | 60 | B/L LE, left forearm |
Y | N/A |
| 9 | 43 | M | NHL | -/F/Sibling/Full | Y | - | 6 | 133 | B/L LE | Y | N/A |
| 10 | 63 | M | CLL | PB/F/Unrelated/Full | Y | 24 | 6 | 44 | R flank | N | N/A |
| 11 | 30 | M | CML | PB/F/Sibling/Full | N | 96 | 5 | 106 | R shoulder |
N | N/A |
Abbreviations: “-“ denotes missing data, AML – Acute mylogenous leukemia; B/L – bilateral; CLL – chronic lymphocytic leukemia; CML – chronic myelogenous leukemia; F – Female; GVHD – Graft-versus-host Disease; HLA – Human leukocyte antigen; L – left; LE – lower extremity; M – Male; MDS – myelodysplastic syndrome; MM – multiple myeloma; NA – Not applicable; NHL – non-hodgkin lymphoma (subtype unknown); PB – peripheral blood graft; pre-B ALL – pre-B cell acute lymphoblastic leukemia; R – Right; RCC renal cell carcinoma; TBI – Total body irradiation; XRT – radiation therapy.